Clinical Trial Detail

NCT ID NCT03613220
Title CompLEEment-1 Canadian Correlative Sub-Study (LEEomic)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

Her2-receptor negative breast cancer

Therapies

Letrozole + Ribociclib

Age Groups: adult child senior

No variant requirements are available.